Published in AIDS Weekly, May 5th, 2003
"A strategy to circumvent immune responses to adenovirus (Ad) resulting from natural infection or repeated vector administrations involves sequential use of vectors from different Ad serotypes," explained X. Nan and colleagues at the National Cancer Institute in Bethesda and Gaithersburg-based GenVec, Inc.
The researchers developed a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.